Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

Conventional chemotherapeutics have been developed into clinically useful agents based
on their ability to preferentially kill malignant cells, generally owing to their elevated …

Regulatory T (Treg) cells play a vital role in maintaining the immunosuppressive tumor
microenvironment. Lactate is a crucial metabolite in cancer and is related to tumor …

Immunotherapy is currently the most rapidly advancing area of clinical oncology, and
provides the unprecedented opportunity to effectively treat, and even cure, several …

Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …

FOXP3-expressing regulatory T (Treg) cells, which suppress aberrant immune response
against self-antigens, also suppress anti-tumor immune response. Infiltration of a large …

The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of
all lung cancer cases. In spite of achievements in understanding the pathogenesis of this …

Background Cancer immunotherapy has changed the standard of care for a subgroup of
patients with advanced disease. Immune checkpoint blockade (ICB) in particular has shown …

Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast
cancer (mTNBC) but only for PD-L1positive disease. The randomized, placebo-controlled …

The tremendous clinical success of checkpoint blockers illustrates the potential of
reestablishing latent immunosurveillance for cancer therapy. Although largely neglected in …